ROSWELL PARK CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma

Not Applicable

Recruiting

Conditions: Plasma Cell Myeloma
Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma
Smoldering Plasma Cell Myeloma

Interventions: Behavioral: Behavioral Intervention
Drug: Propranolol
Drug: Beta-Adrenergic Antagonist
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Other: Short-Term Fasting
Other: Resistance Training

First Posted Date: 2022-04-05

Last Posted Date: 2024-11-25

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 175

Registration Number: NCT05312255

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Quality of Life Intervention to Inform Patient Decision-Making in Early-Stage Lung Cancer

Not Applicable

Recruiting

Conditions: Lung Non-Small Cell Carcinoma
Stage I Lung Cancer AJCC v8
Stage IA2 Lung Cancer AJCC v8
Stage IB Lung Cancer AJCC v8
Stage II Lung Cancer AJCC v8
Stage IIA Lung Cancer AJCC v8
Stage IA1 Lung Cancer AJCC v8
Stage IA3 Lung Cancer AJCC v8
Stage IIB Lung Cancer AJCC v8

Interventions: Other: Informational Intervention
Other: Best Practice
Other: Questionnaire Administration

First Posted Date: 2022-03-23

Last Posted Date: 2025-02-04

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 150

Registration Number: NCT05292521

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Phase 2

Recruiting

Conditions: Recurrent Fallopian Tube Serous Adenocarcinoma
Recurrent Platinum-Resistant Ovarian Carcinoma
Recurrent Primary Peritoneal Clear Cell Adenocarcinoma
Recurrent Primary Peritoneal Serous Adenocarcinoma
Recurrent Ovarian Endometrioid Adenocarcinoma
Recurrent Endometrial Serous Adenocarcinoma
Platinum-Sensitive Ovarian Carcinoma
Recurrent Fallopian Tube Carcinoma
Recurrent Fallopian Tube Endometrioid Adenocarcinoma
Recurrent Ovarian Carcinoma

Interventions: Biological: Anti-CD40 Agonist Monoclonal Antibody CDX-1140
Biological: Bevacizumab
Biological: Pembrolizumab
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2022-02-09

Last Posted Date: 2025-05-22

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 80

Registration Number: NCT05231122

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Virtual Intervention to Improve Medication Adherence in Pediatric Cancer: MedSupport

Not Applicable

Completed

Conditions: Medication Adherence

Interventions: Behavioral: Patient participation
Other: Clinician barrier reports

First Posted Date: 2021-12-08

Last Posted Date: 2024-07-17

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 17

Registration Number: NCT05150028

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

A Pilot Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) in Central Non-Small Cell Lung Cancer

Not Applicable

Active, not recruiting

Conditions: Non Small Cell Lung Cancer

Interventions: Radiation: SBRT

First Posted Date: 2021-12-01

Last Posted Date: 2025-04-24

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 30

Registration Number: NCT05138900

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Sleep and Circadian Rhythm Study in Head and Neck Cancer Patients

Not Applicable

Withdrawn

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Other: Counseling
Other: Educational Intervention
Procedure: Biospecimen Collection
Other: Questionnaire Administration
Other: Electronic Health Record Review
Other: Medical Device Usage and Evaluation

First Posted Date: 2021-10-29

Last Posted Date: 2022-01-12

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT05099952

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Mindfulness Meditation

Not Applicable

Completed

Conditions: Cancer

Interventions: Behavioral: Mindfulness program

First Posted Date: 2021-10-28

Last Posted Date: 2024-02-16

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 57

Registration Number: NCT05098002

Locations: 🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Phase 1

Terminated

Conditions: Stage IV Prostate Cancer AJCC v8
Stage IVA Prostate Cancer AJCC v8
Stage IVB Prostate Cancer AJCC v8
Castration-Resistant Prostate Carcinoma

Interventions: Drug: Decitabine and Cedazuridine
Drug: Enzalutamide

First Posted Date: 2021-09-08

Last Posted Date: 2025-02-28

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 8

Registration Number: NCT05037500

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Comparing Nicotine Delivery, Subjective Effects, and Sensory Experiences of Tobacco Users Using Oral Nicotine Products and Electronic Cigarettes [ZYN Study]

Not Applicable

Completed

Conditions: Tobacco Smoking
Tobacco Use
Cigarette Smoking
Smokeless Tobacco Cessation

Interventions: Other: Electronic Cigarette
Other: Oral Nicotine Pouch

First Posted Date: 2021-09-01

Last Posted Date: 2023-10-26

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 15

Registration Number: NCT05030194

Locations: 🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

Phase 2

Recruiting

Conditions: Fallopian Tube Serous Adenocarcinoma
Ovarian Clear Cell Adenocarcinoma
Primary Peritoneal Endometrioid Adenocarcinoma
Fallopian Tube Carcinosarcoma
Ovarian Endometrioid Adenocarcinoma
Ovarian Serous Adenocarcinoma
Primary Peritoneal Carcinosarcoma
Recurrent Ovarian Carcinoma
Fallopian Tube Clear Cell Adenocarcinoma
Ovarian Carcinosarcoma

Interventions: Procedure: Biopsy
Biological: Bevacizumab
Procedure: Biospecimen Collection
Drug: Pegcetacoplan
Biological: Pembrolizumab
Other: Questionnaire Administration

First Posted Date: 2021-06-09

Last Posted Date: 2025-05-11

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 60

Registration Number: NCT04919629

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

AI-Powered Research

Premium Access

ROSWELL PARK CANCER INSTITUTE

Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma

Quality of Life Intervention to Inform Patient Decision-Making in Early-Stage Lung Cancer

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

A Virtual Intervention to Improve Medication Adherence in Pediatric Cancer: MedSupport

A Pilot Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) in Central Non-Small Cell Lung Cancer

Sleep and Circadian Rhythm Study in Head and Neck Cancer Patients

Mindfulness Meditation

Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Comparing Nicotine Delivery, Subjective Effects, and Sensory Experiences of Tobacco Users Using Oral Nicotine Products and Electronic Cigarettes [ZYN Study]

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion